Aleglitazar | |
---|---|
(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 7-benzothiophenyl]propanoic acid |
|
Other names
Ro-0728804, R-1439 |
|
Identifiers | |
CAS number | 475479-34-6 |
PubChem | 10274777 |
ChemSpider | 8450255 |
DrugBank | DB08483 |
KEGG | D08845 |
ChEMBL | CHEMBL519504 |
Jmol-3D images | Image 1 Image 2 |
|
|
|
|
Properties | |
Molecular formula | C24H23NO5S |
Molar mass | 437.50812 |
(verify) (what is: / ?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
Infobox references |
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which is being developed by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is currently in phase II clinical trials.[2]
|